Preclinical evidence in melanoma demonstrated its ability to induce anoikis and suppress metastasis in human melanoma cells, interrupting ECM attachment and FAK phosphorylation, and resulting in caspase activation through a decrease in the Bcl-2/Bax protein ratio (Zhang et al., 2011). Here, PTK2 is linked to melanoma.